


**Product Name** : HRS-4642  
**Cat. No.** : PC-22656  
**CAS No.** : 2836263-09-1  
**Molecular Formula** : C<sub>34</sub>H<sub>35</sub>F<sub>3</sub>N<sub>6</sub>O<sub>3</sub>  
**Molecular Weight** : 632.69  
**Target** : Ras  
**Solubility** : 10 mM in DMSO



CAS: 3033864-81-9

## Biological Activity

HRS-4642 is a high affinity, selective, long-acting, and non-covalent **KRAS G12D** inhibitor with SPR KD of 0.083 nM, >20-fold selective over wild-type KRAS and KRAS G12C.

HRS-4642 binds to KRAS G12D in both GDP- and GTP-bound forms.

HRS-4642 selectively inhibits the interaction between GDP-loaded KRAS G12D and SOS1 with IC<sub>50</sub> of 0.72 nM.

HRS-4642 inhibits cellular RAS activity in the KRAS G12D-mutant cell line with IC<sub>50</sub> of 2.329 nM in AsPC-1 cells, >350-fold selective over PC9 cells.

HRS-4642 selectively hindered the binding of GTP-loaded KRAS G12D to RAF1, a crucial downstream effector of the KRAS signaling pathway with IC<sub>50</sub> of 5.9 nM.

HRS-4642 showed dose-dependent inhibition of cellular p-MEK and p-ERK levels in cell lines harboring KRAS G12D mutation.

HRS-4642 exhibited high selectivity in inhibiting the growth of KRAS G12D-mutant cell lines, with IC<sub>50</sub> values ranging from 0.55 to 66.58 nM, but not G12C, G12V, G12S, G12A, G13D, and wild type cells.

HRS-4642 (7.5 or 15 mpk) inhibits tumor growth in KRAS G12D-mutant GP2d xenograft model in BALB/c nude mice.

## References

Zhou C, et al. *Cancer Cell*. 2024 Jul 8;42(7):1286-1300.e8.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com